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Abstract
Background: In cirrhotic patients with hepatocellular carcinoma (HCC), poor differentiation in pre-liver
transplantation (LT) biopsy of the largest tumour is used as a criterion for exclusion from LT in some
centres. The potential role of pre-LT biopsy at one centre was explored.
Methods: A prospective database of patients undergoing orthotopic LT for radiologically diagnosed
HCC at St James's University Hospital, Leeds during 2006–2011 was analysed.
Results: A total of 60 predominantly male (85.0%) patients with viral hepatitis were identified. There were
discrepancies between radiological and histopathological findings with respect to the number of tumours
identified (in 27 patients, 45.0%) and their size (in 63 tumours, 64.3%). In four (6.7%) patients, the largest
lesion, which would theoretically have been targeted for biopsy, was not the largest in the explant. Nine
(31.0%) patients with multifocal HCC had tumours of differing grades. In two (6.9%) patients, the largest
tumour was well differentiated, but smaller tumours in the explant were poorly differentiated. In one
patient, the largest lesion was benign and smaller invasive tumours were confirmed histologically.
Conclusions: The need to optimize selection for LT in HCC remains. In the present series, the largest
tumour was not always representative of overall tumour burden or biological aggression and its potential
use to exclude patients from LT is questionable.
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Introduction
Liver cancer is the sixth most common cancer worldwide and
remains the third most common cause of cancer-related death.1
Hepatocellular carcinoma (HCC) accounts for 90% of primary
hepatic malignancies and its incidence in the UK has doubled over
the last 30 years, with the majority of HCCs arising on a back-
ground of chronic liver disease.2,3 Liver resection is effective in
patients with early cirrhosis and preserved liver function, but liver
transplantation (LT) remains the treatment of choice in patients
with more severe underlying cirrhosis, portal hypertension or
multifocal disease.4–7 In these patients the introduction of selec-
tion criteria, such as those generated in Milan in 1996, aimed to
optimize individual patient outcomes and rationalize the use of
limited organ resources. This resulted in dramatic improvements
in outcomes.8 Today, survival rates in patients transplanted within
and indeed beyond these criteria now match those in patients
undergoing transplantation for cirrhosis alone.8–12 Despite this,
although HCC now accounts for 25% of all indications for LT in
Europe, only 5% of patients with HCC actually undergo LT.13,14
The increasing incidence of HCC, ever-improving management
approaches for underlying causative liver diseases, shortage of
cadaveric donor organs and the advent of live-donor LT have led
to calls for the expansion of selection criteria.15 Conversely, given
This manuscript was presented at the 10th World IHPBA Congress, Paris,
1–5 July 2012 and at the European Society for Organ Transplantation
(ESOT) Congress.
Correction added on February 11, 2013, after first online publication: Gareth
Morris-Stiff was added to the author list.
DOI:10.1111/hpb.12008 HPB
HPB 2013, 15, 418–427 © 2012 International Hepato-Pancreato-Biliary Association
the limited supply of organs, others have cautioned that such an
expansion should not be to the detriment of non-HCC recipients
who remain on waiting lists.16 There is a need to reassess existing
criteria and identify the patients who are likely to benefit most
from receiving a transplant.
Despite significant advances in non-invasive imaging tech-
niques, discrepancy between preoperative radiological assessment
of lesions and explant pathological examination remains. Misdi-
agnosis still occurs in up to 20% of patients and staging errors in
20–30% highlight the challenges of accurately characterizing
lesions pre-LT.15,17
The role of preoperative biopsy in HCC remains a source of
controversy in the transplant community. In conventional onco-
logical practice, biopsies provide histological confirmation of
malignancy and are requisite before starting treatment. Increas-
ingly, in the era of molecular diagnostics this can inform and
personalize treatment and prognostication. Conversely, in HCC
the use of pretreatment biopsy is reserved for a minority of
complex clinical cases or diagnostic dilemmas.18 However, some
specialist centres currently advocate the use of pre-LT biopsy as
part of a staging and selection process. Once HCC has been diag-
nosed, based on established criteria on cross-sectional imaging
with or without elevation of alpha-fetoprotein (AFP), the patient
undergoes a biopsy.19,20 Findings of high-grade or poor differen-
tiation in a single HCC, or the largest tumour in multifocal
disease, are regarded as markers of aggressive underlying tumour
biology and poor prognosis and are used to exclude patients from
transplantation and consign them to non-curative treatments. It is
proposed that tumour grade on pre-LT biopsy predicts the bio-
logical behaviour of tumours, adding significant prognostic
power to static morphological selection criteria.
Biopsy of the largest tumour may provide evidence of aggres-
sive tumour biology. Indeed, studies have confirmed that tumour
size is positively correlated with vascular invasion, recurrence and
survival.18 Therefore, the dominant tumour in multifocal disease
may represent an accessible and potentially representative target.
However, if a biopsy fails to demonstrate poor differentiation, the
possibility that other areas of the sampled lesion and smaller
synchronous tumours may show poor differentiation remains.
The undetected presence of poor differentiation may have signifi-
cant prognostic consequences.
This study was conducted using a prospectively maintained
database at a tertiary referral centre in the UK to explore the
potential role of pre-LT biopsy as a selection or exclusion criterion
for LT.
Materials and methods
A retrospective analysis of a prospectively maintained departmen-
tal database of all patients with a pre-LT radiological diagnosis of
HCC undergoing LT at St James’s University Hospital, Leeds, UK,
was conducted. Patients with a radiological diagnosis of HCC at
the time of listing and diagnosed with end-stage liver disease
whilst on the waiting list were included. Consecutive patients
transplanted during 2006–2011 were analysed. The database was
cross-referenced with UK Transplant Service (UKTS) records to
ensure completeness. Demographic data, selection criteria param-
eters and clinical factors including aetiology, timing of imaging
and treatment were recorded. One patient was excluded because
fibrolamellar HCC was diagnosed on histological examination of
the explant.
Pre-LT diagnoses of HCC were made in accordance with the
European Association for the Study of the Liver (EASL) and the
American Association for the Study of Liver Diseases (AASLD)
guidelines. All patients underwent multidisciplinary team assess-
ment and standardized diagnostic dual contrast-enhanced mag-
netic resonance imaging (DCE-MRI) with gadolinium and
superparamagnetic iron oxide, performed and reported by spe-
cialist hepaticopancreaticobiliary (HPB) radiologists.21–24 If subse-
quent DCE-MRI scans were undertaken following diagnosis, the
scan closest to the LT was used to stage the disease. During 2006–
2008, the unit’s selection policy was in accordance with the Milan
Criteria; from 2008 onwards, the unit adopted the UK HCC trans-
plantation criteria.8,25
Routine histopathological examination of all explanted livers
was undertaken and the reports were correlated with DCE-MRI
assessments. Lesions on DCE-MRI were identified on the basis of
their size and location in the explant. Histopathological examina-
tion and reporting were undertaken by two specialist HPB
pathologists. Explanted livers were sliced at a thickness of 5 mm
and subjected to visual inspection. Areas identified as dysplastic or
neoplastic by DCE-MRI, large nodules and samples representative
of diffuse liver disease were identified at macroscopic examination
and submitted for histological evaluation. Tumours were exten-
sively sampled in order to obtain representative samples for
grading. Histopathological reports included data on number of
tumours, maximum diameter of all tumours measured on the
gross specimen, distribution, macrovascular or microvascular
invasion and histological grade based on the degree of tumour
differentiation.26 Total tumour volume was calculated as the sum
of individual tumour volumes, which is calculated as 4/3 ¥ p ¥ r 3.
At least one block was sampled from each tumour and more
blocks were sampled from larger tumours. Tumour grade was
determined by the poorest degree of differentiation found within
a lesion. Tumours were staged according to the Union for Inter-
national Cancer Control (UICC)/American Joint Committee on
Cancer (AJCC) staging system for HCC.27
Accurate radiological staging was defined as agreement with
histopathological examination on tumour number and size
(cumulative tumour diameter within 5 mm). Under-staging was
defined as a higher tumour number or size (>5 mm larger in
cumulative diameter), whereas over-staging was defined as a lower
tumour number or size (>5 mm smaller in cumulative diameter).
The interval between index diagnostic imaging and transplanta-
tion was also recorded in order to interrogate the potential con-
tribution of disease progression prior to LT.
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Once listed for LT, 18 (30.0%) patients received additional
treatment in the form of transarterial chemoembolization and
five (8.3%) patients underwent radiofrequency ablation (RFA)
according to standard procedures within the department to
restrict tumour progression. One patient underwent a pre-LT
biopsy.
Immunosuppressive regimens after transplantation were pre-
scribed in accordance with departmental protocols (either
cyclosporin or tacrolimus with azathioprine or mycophenolate).
Patients did not receive routine adjuvant chemotherapy after
transplantation and were followed up regularly for tumour recur-
rence by computed tomography (CT) scanning. Patients at risk for
hepatitis B virus recurrence were treated with HBIg and oral anti-
viral agents. The median length of follow-up was 24 months
(range: 6–65 months).
Endpoints
Tumour recurrence was identified by regular CT scanning. Time
to recurrence from diagnostic radiological investigation was
recorded in months, along with the date and cause of death.
All-cause mortality is reported because it is the most clinically
relevant outcome and avoids underestimation of the impact of
HCC. For patients still alive, follow-up ended at the last clinic
appointment (censored).
Statistics
All statistical analyses were performed using spss Version 18.0
(SPSS, Inc., Chicago, IL, USA). Student’s t-test, Mann–Whitney
U-test and related-samples Wilcoxon signed rank tests were used
as appropriate. The Kaplan–Meier technique was used to calculate
survival. Log-rank (Mantel–Cox) and Cox proportional hazards
models were used for univariate and multivariate analyses, respec-
tively. Variables with P-values of <0.2 were entered into the model
for multivariate analysis. A P-value of <0.05 was considered to
indicate statistical significance.
Results
Patient characteristics and tumour aetiology are shown in Table 1,
demonstrating a representative UK cohort with a male prepon-
derance and predominantly viral underlying aetiology.
Radiological assessment
The median time between preoperative DCE-MRI and LT was
52.5 days (range: 5–339 days). Based on preoperative radiological
assessment, 34 (56.7%) patients had a single HCC and 26 (43.3%)
had multifocal disease. The median number of tumours was one
(range: 1–6) and the median tumour size was 16 mm (range:
5–60 mm). The majority (98.4%) of tumours measured <50 mm.
The cumulative tumour diameter was <80 mm in the majority of
patients (n = 56, 93.3%) and tumour distribution was predomi-
nantly unilobar (90.0% versus 10.0%). Most patients fulfilled the
Milan Criteria (n = 49, 81.7%).
Histopathological assessment
Explant histopathological examination demonstrated that all
patients had cirrhosis in the background liver tissue. Overall, the
tumour burden in the explants was similar to that in radiological
assessment. A total of 31 (51.7%) patients had a single HCC and
29 (48.3%) had multiple tumours. The median number of
tumours was one (range: 1–9) (P = 0.819 versus radiological
assessment) (Fig. 1). Subgroup analysis revealed a trend towards
an increase in the proportion of patients with more than three
tumours on pathological examination compared with radiologi-
cal assessment [n = 9 (15.0%) versus n = 6 (10.0%); P = 0.180].
This resulted in an increase in the number of patients transplanted
in whom disease in the explant fell outwith the Milan Criteria [n
= 19 (31.7%) versus n = 11 (18.3%); P = 0.037]. As disease pro-
gression during the interval between DCE-MRI and LT may con-
tribute to this increase, the delay between scanning and LT was
analysed. There was a significantly longer interval between DCE-
MRI and LT in these upstaged patients (111.6 days versus 61.3
days; P = 0.016).
On an individual patient basis, in almost half of patients (n =
27, 45.0%) a discrepancy emerged between the total number of
tumours identified in preoperative radiological imaging and that
found in explant histopathological examination. The number of
tumours was underestimated by DCE-MRI in 17 (28.3%) patients
and overestimated in 10 (16.7%).
Overall, median tumour size was 15 mm (range: 3–55 mm) (P
= 0.679 versus radiological assessment) (Fig. 1). The proportion of
patients with a cumulative tumour diameter of <80 mm was
similar to that derived from radiological examinations (n = 54,
90.0%; P = 0.666 versus radiological assessment). However, when
individual tumours were considered, size discrepancies emerged
in almost two thirds of all HCCs (n = 63, 64.3%). Radiological
assessment overestimated lesion size in 34.2% of lesions and
underestimated it in 30.1%. Most discrepancies occurred in
lesions at the extreme ends of the range of sizes; this may partially
reflect both the detection limits of MRI for small tumours and
ability to accurately measure large lesions histologically. Neverthe-
less, in four (6.7%) patients, the largest lesion identified radiologi-
cally was not the largest lesion identified histologically (Fig. 2).
A total of 129 tumours were identified in explants with a range
of grades of differentiation: 39 (30.2%) were well differentiated;
66 (51.2%) were moderately differentiated, and 24 (18.6%) were
poorly differentiated. Of 29 patients with multifocal HCC, one
third (n = 9, 31.0%) had tumours of differing histological grades.
In two patients (6.9%), the largest tumour, which would have
been targeted for preoperative biopsy, was shown to be well dif-
ferentiated HCC, whereas other smaller tumours in the explant
were poorly differentiated HCCs. One of these patients had
primary biliary cirrhosis with three HCCs, of which one measured
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Table 1 Clinicopathological characteristics of the study cohort
Characteristic Demographic data Radiological data Histopathological data
Age, years, median (range) 58 (27–73)
Gender, n (%)
Male 51 (85.0%)
Female 9 (15.0%)
Aetiology of cirrhosis, n (%)
Hepatitis C virus 34 (56.7%)
Hepatitis B virus 2 (3.3%)
Alcoholic liver disease 11 (18.3%)
Cryptogenic 2 (3.3%)
Haemochromatosis 4 (6.7%)
Others 7 (11.7%)
MELD score, median (range) 17.5 (7–29)
AFP, ng/ml, mean (range) 169.64 (27–4585.3)
Time to transplantation, days, median (range) 52.5 (5–339)
Preoperative bridging treatments, n (%)
Chemoembolization 18 (30.0%)
Radiofrequency ablation 5 (8.3%)
Milan Criteria, in/out 49/11 44/16
UCSF Criteria, in/out 58/2 49/11
Total tumour volumea, n (%)
<115 cm3 42 (70.0%)
>115 cm3 18 (30.0%)
Tumour number, n (%)
1 34 (56.7%) 31 (51.6%)
2 15 (25.0%) 13 (21.7%)
3 5 (8.3%) 6 (10.0%)
>3 6 (10.0%) 10 (16.7%)
Tumour size, n (%) Range: 0.5–6 cm Range: 0.3–5.5 cm
<1 cm 33 (29.5%) 32 (24.8%)
1–3 cm 62 (55.4%) 68 (52.7%)
3–5 cm 14 (12.5%) 26 (20.2%)
>5 cm 3 (2.6%) 3 (2.3%)
Tumour distribution, n (%)
Unilobar 54 (90.0%) 54 (90.0%)
Bilobar 6 (10.0%) 6 (10.0%)
Vascular invasion, n (%)
Macroscopic 0 1 (1.7%)
Microscopic N/A 11 (18.3%)
None 60 (100%) 48 (80.0%)
TNM stagingb, n (%)
I N/A 29 (49.2%)
II N/A 26 (44.1%)
IIIa N/A 4 (6.7%)
IIIb N/A 0
IIIc N/A 0
IV N/A 0
Differentiation, n (%)
Good N/A 39 (30.2%)
Moderate N/A 66 (51.2%)
Poor N/A 24 (18.6%)
aCalculated as the sum of the volume of all tumours [(4/3) ¥ p ¥ r3 where r is the maximum radius of each tumour in cm].
bUnion for International Cancer Control/American Joint Committee on Cancer staging system for hepatocellular carcinoma.
MELD, Model for End-stage Liver Disease; AFP, alpha-fetoprotein; UCSF Criteria, University of California San Francisco Criteria (single tumour < 6.5 cm or up to three
tumours with a largest lesion of 4.5 cm and total tumour diameter of 8.0 cm); TNM, tumour–node–metastasis; N/A, not applicable.
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50 mm and was well differentiated, one measured 15 mm and was
moderately differentiated, and one measured 18 mm and was
poorly differentiated. The other patients had alcoholic liver
disease with one 30-mm, well-differentiated HCC and one 8-mm,
poorly differentiated HCC.
Of those lesions specifically diagnosed as HCC on pre-LT
imaging, 98 were identified and available for histological exami-
nation. In five patients with single HCCs, on pre-LT DCE-MRI,
more than one HCC was found in the explant. Only the tumour
identified preoperatively was considered for this part of the study.
Some HCCs diagnosed preoperatively could not be identified in
the explants (n = 3) and some were completely destroyed by bridg-
ing therapy and were excluded (n = 6). Of the remaining 89
lesions, 77 (86.5%) were confirmed histologically as HCC and the
remainder were identified as regenerative nodules (n = 6, 6.7%),
dysplastic nodules (n = 4, 4.5%) or indeterminate despite exten-
sive histological examination (n = 2, 2.2%).
In the present series, one patient underwent a diagnostic preop-
erative ultrasound-guided biopsy of a suspicious lesion. This
patient had hepatitis C virus (HCV) infection and three lesions on
DCE-MRI, two of which were thought to be highly suspicious for
HCC. The largest (36 mm) was biopsied to reveal a small sample
of a well-differentiated hepatocellular lesion. Within the limita-
tion of the small sample size, this lesion was thought to be a
dysplastic nodule with no definite evidence of HCC. Post-LT, this
lesion was identified in the explant and showed features of a
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Figure 1 Tumour burden. (a) Number and (b) size of hepatocellular
carcinomas detected by radiological and histological examination.
Data are given as median  interquartile range (IQR). Outliers
denoted by  = values  third quartile plus 1.5 times the IQR and
* = values  third quartile plus three times the IQR. Radiological
versus histological assessment: P > 0.05, Mann–Whitney U-test
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Figure 2 Radiological versus pathological identification and assess-
ment of tumours. (a) Number of individual hepatocellular carcinomas
(HCCs) detected by radiological and histological examination on a
per patient basis. (b) Size of individual HCCs detected by radiologi-
cal and histological examination on a per lesion basis. All lesions
identified on dual contrast-enhanced magnetic resonance imaging
and in explants are displayed. Tumours that underwent bridging
therapy are not displayed
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dysplastic nodule. However, two other lesions in the explant that
were not biopsied pre-LT were found to be well-differentiated
HCCs.
Downstaging
In the group of patients undergoing bridging therapy, as expected,
more patients were found to exceed the Milan Criteria [five of 23
(21.7%) versus six of 37 (16.2%) not undergoing bridging treat-
ment]. Three (8.7%) of the treated patients were subsequently
downstaged to within the Milan Criteria on pathological assess-
ment. Conversely, in three (8.7%) patients, disease was initially
identified as within the Milan Criteria but subsequently pro-
gressed beyond the Milan Criteria despite bridging therapy. In the
present series, median waiting time to receipt of a graft was
slightly shorter in patients undergoing bridging therapy (37 days
versus 63 days; P = 0.036).
Patient outcomes
In the present series, 1- and 3-year absolute overall survival rates
were 83.1% and 81.0%, respectively (Fig. 3). Two patients experi-
enced recurrence; in one of these patients extrahepatic pelvic
metastatic disease occurred within 13 months of LT. This patient
had HCV cirrhosis and four HCCs identified on DCE-MRI as
beyond the Milan Criteria and underwent RFA therapy prior to
LT. Pre-LT AFP was 3372 ng/ml. Pathological assessment con-
firmed nine viable HCCs in the explant and classed the disease as
stage IIIa. There was no microvascular invasion and all tumours
were moderately differentiated. A second patient died from pul-
monary metastatic disease within 8 months of LT. This patient was
also infected with HCV and had a single HCC within the Milan
Criteria. Pre-LT AFP in this patient was normal at 11 ng/ml. The
explant showed stage II disease with three HCCs, two of which,
including the radiologically identified largest tumour, were poorly
differentiated. No microvascular invasion was identified.
Interestingly, both of the patients with well-differentiated
largest tumours, but other smaller poorly differentiated tumours
in the liver remained alive without recurrence after 27 months and
55 months of follow-up, respectively.
Prognostic factors
Univariate analysis revealed that the presence of poor differentia-
tion in the largest lesion, the presence of poor differentiation in
any lesion in the explant, microvascular invasion and HCC recur-
rence were significant prognostic markers for survival (P < 0.05).
However, following multivariate analysis, microvascular invasion
was the only independently significant variable for survival
[hazard ratio (HR) = 5.959, 95% confidence interval (CI) 1.35–
26.39)] (Table 2). This loss of significance is most likely to be
attributable to the small number of terminal events in this series
and the significant correlation between microvascular invasion
and poor tumour differentiation (c2 = 5.963, P = 0.015). The
presence of poor differentiation in any lesion in the explant,
the presence of poor differentiation in any smaller lesion (i.e. the
non-largest HCC) and pre-transplant AFP of >400 ng/ml were
significant univariate predictors of HCC recurrence in this series
(P < 0.05).
Discussion
The demand for donor organs continues to far outstrip supply and
HCC is one of the fastest-growing indications for LT worldwide.27
This has led to mounting pressure to ensure the optimal use of
available grafts and calls for the modification of HCC LT selection
criteria and treatment protocols. The ability to reliably assess
tumour biology pre-LT would allow accurate prognostication and
inform treatment decisions. Beyond the direct impact on recipi-
ents, more effective allocation strategies would minimize indirect
detrimental impact on those patients without HCC who remain on
LT waiting lists, thereby improving collective outcomes. Current
radiological staging has limitations and strategies to enhance its
utility are required. Evidence on the prognostic value of poor
tumour differentiation continues to accumulate.20,28–33 This makes
the use of a pre-LT staging biopsy to select and prioritize patients
on the basis of tumour grade an attractive strategy that has been
adopted by several groups.19,20
The present study highlights important issues surrounding
pre-LT staging biopsy that require careful consideration. In two
(8.7%) patients with multifocal disease, biopsy of the largest
tumour would theoretically have revealed falsely reassuring histo-
logical grading. In these patients, the largest lesions diagnosed
radiologically as HCC were found to be well-differentiated
tumours on histopathological examination of explanted material.
However, crucially both patients had other smaller, poorly differ-
entiated HCCs within the liver. Proponents of staging biopsy
deem the presence of poor differentiation to confer a prognosis
poor enough to justify the patient’s exclusion from LT. Even if this
principle is accepted, the present data make it clear that reliably
identifying the largest lesion and obtaining a representative diag-
nostic biopsy from it presents significant challenges.
In the present study, explants from patients with multifocal
HCC showed individual tumours of differing grades in 34.6% of
cases. This represents a significant fraction of these patients and,
indeed, 15.0% of all patients undergoing LT for HCC. Given this,
a potential for misleading pre-LT biopsy certainly exists. Further-
more, the definition of the largest pre-LT lesions can also be prob-
lematic. In the present series, discrepancies between radiologically
and histologically defined largest lesions emerged in 7.7% of cases.
Sampling error, and inter- and intra-observer variability in histo-
logical assessment of tumours will also influence the reliability of
staging biopsy.
One patient in this series underwent a pre-LT biopsy which
revealed a dysplastic nodule, subsequently shown to be a well-
differentiated HCC in the explant. This patient had end-stage
HCV cirrhosis and although this patient’s treatment strategy was
not altered by the biopsy findings, this particular case highlights
the limitations and technical challenges of histopathological
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Figure 3 Kaplan–Meier survival curves in hepatocellular carcinoma (HCC). (a) Overall survival was 54.23 months [95% confidence interval
(CI) 47.78–60.68]. (b) Univariate analysis demonstrated that overall survival was significantly reduced if the largest HCC was poorly
differentiated (P = 0.027). (c) Only microvascular invasion (MVI) was identified as an independent predictor in multivariate analysis (hazard
ratio = 5.96, 95% CI 1.36–26.39; P = 0.019)
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examination of biopsy specimens. Non-representative sampling of
heterogeneous tumours is a significant problem. A recent review
estimates the specificity and positive predictive value of diagnostic
liver biopsy for suspected HCC in cirrhotic patients to be 100%,
with a correspondingly infinitely high positive likelihood ratio
(LHR) of >10 indicating its ability to rule in the diagnosis.19,34,35 By
contrast, biopsies typically achieve sensitivity of 86–90%. This
falls to 83% for lesions of <10 mm in size and to 66% if a smaller
needle (21–22-gauge) is used. Negative predictive values vary (13–
75%) and the negative LHR is 0.07–0.34 (values of < 0.1 provide
strong evidence of a test’s ability to rule out a diagnosis). Further-
more, it is estimated that despite image guidance, which is
dependent upon the size and location of a tumour, 2–11% of
biopsy specimens will be inadequate for diagnostic examination
by the pathologist.34 One previous study specifically examined the
ability of pre-LT needle core biopsies of HCC to predict the grade
on formal histopathological examination of explanted speci-
mens.36 Its authors reported a relatively poor predictive ability
[k-statistic = 0.38, receiver operating characteristic (ROC) area
under the curve (AUC) = 0.74] with a correspondingly poor
ability to predict the presence of microvascular invasion and
outcome compared with formal grading of the tumour in the
explanted liver.36
Proponents of biopsying argue that high-quality data from
centres that regularly carry out biopsies prove it to be safe and
effective with very low rates of needle track seeding.19,37 At the
Barcelona Clinic, rates of needle track seeding are 0.01% and
evidence for the safety of laparoscopic biopsy accumulates.38 In a
meta-analysis of eight studies conducted in 2008, the authors
concluded that the overall incidence of seeding was 2.7% (95% CI
1.8–4.0) or 0.9% per year, with all occurrences treated successfully
without impact on operability or survival.39–47 Strategies to
improve the safety of biopsy and reduce seeding have been pro-
posed, such as the use of a coaxial biopsy needle with an intro-
ducer, which would allow for multiple passes of the needle with
the protective introducer remaining in place, although these have
not been rigorously tested.45
The increasing use of bridging therapy may also influence the
utility of pre-LT biopsy. Although predominantly used as an initial
tool in treatment selection protocols before any bridging therapy,
there may be occasions when patients who have undergone these
treatments require assessment or reassessment for LT. The
response to initial bridging or downstaging therapy is itself pro-
posed as a marker of tumour biology, prognosis and a selection
parameter and may become more important with the increased
use of downstaging therapy.48 The effects of these treatments will
clearly influence the ability of pre-LT biopsy to accurately stage
such lesions. In the present study, the majority of those treated
with bridging therapy demonstrated at least some viable HCC
present in the explants, although some had been completely
destroyed. Whether those persisting neoplastic regions would
have theoretically been sampled in a biopsy remains unknown.
The present study utilized formal histological examinations of
explant specimens, often supplemented with specialized immu-
nostaining techniques, to speculate on the potential findings of
theoretically obtainable small needle core biopsies. As this and
previous studies have highlighted, the representative nature of such
biopsy samples remains controversial.36,37,49 Emerging molecular
techniques may enhance examinations of biopsy specimens and
indeed become helpful in risk stratification. However, they remain
far from routine in clinical practice and do not remove the error
inherent in the sampling of heterogeneous tumours.50
Table 2 Cox proportional hazards model for multivariate recurrence and survival analysis
Multivariate analysis
B SE Wald d.f. P-value Exp(B) 95% CI for Exp(B)
Recurrence
Poor differentiation of any HCC 10.078 232.630 0.002 1 0.965 23811.103 0.000–24630
Sex 5.240 35.732 0.022 1 0.883 188.616 0.000–4907
MELD score -0.225 0.204 1.219 1 0.270 0.798 0.535–1.191
Differentiation of smaller HCC 7.658 35.689 0.046 1 0.830 2116.489 0.000–5056
Alpha-fetoproteina 0.855 1.682 0.259 1 0.611 2.352 0.087–63.538
Survival
Poor differentiation of any HCC 0.747 1.275 0.343 1 0.558 2.110 0.173–25.699
Poor differentiation of largest HCC -0.546 1.363 0.161 1 0.689 0.579 0.040–8.378
Microvascular invasion 1.785 0.759 5.528 1 0.019 5.959 1.346–26.387
Sex 0.737 0.881 0.700 1 0.403 2.090 0.372–11.750
Recurrence 1.745 1.023 2.911 1 0.088 5.726 0.771–42.514
MELD score -0.008 0.058 0.019 1 0.891 0.992 0.886–1.111
aAlpha-fetoprotein was stratified as > 400 ng/ml versus < 400 ng/ml.
SE, standard error; 95% CI, 95% confidence interval; HCC, hepatocellular carcinoma; Poor differentiation of any HCC, the presence of at least one
poorly differentiated HCC in the explants; Poor differentiation of smaller HCCs, the presence of poor differentiation in any of the non-largest HCCs;
MELD, Model for End-stage Liver Disease.
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In patients with a well-differentiated largest tumour and
smaller coexisting poorly differentiated tumours, biopsy may still
have a potential role. Sampling of multiple lesions would allow
more accurate staging, but the significantly increased risks are
likely to negate any added benefit, whatever modality of biopsy is
used. In the future, other novel radiological assessments could be
used to target the biologically most aggressive lesion for biopsy.
Some evidence supporting the role of positron emission tom-
ograpghy (PET)-CT for non-invasive staging has been reported,
but this requires further study and validation.51–53 The targeted
biopsy of lesions likely to be poorly differentiated according to
PET-CT criteria could be one potential approach. Non-invasive
dynamic and molecular imaging techniques to assess tumour
biology are also under development and may circumvent the need
for biopsy altogether.54,55
In conclusion, the present results suggest there is currently a
limited role for routine pre-LT HCC staging biopsy at this par-
ticular centre. In multifocal disease, the largest lesion was not
always representative of tumour burden or biological aggression
and its potential use to select or exclude patients from curative
treatment is questionable. Equally, the ability to accurately iden-
tify and obtain representative biopsy samples from the largest
lesion can be difficult with currently available techniques. The
accuracy of static radiological staging remains suboptimal and
there is certainly a need for alternative strategies to improve treat-
ment and selection. There are still unanswered questions sur-
rounding staging biopsy which require further study, possibly
with the use of more advanced statistical modelling techniques.
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